BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Abpro partners with Celltrion to advance ABP-102, a bispecific antibody for HER2+ cancers
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Abpro partners with Celltrion to advance ABP-102, a bispecific antibody for HER2+ cancers
Sep. 22, 2022
No Comments
Abpro Corp. has entered into a strategic partnership with Celltrion Holdings Co. Ltd. for ABP-102, a bispecific antibody therapy for patients with HER2+ cancer, including breast, gastric and pancreatic cancers.
BioWorld Science
Collaboration
Cancer
Bispecific antibody
Immuno-oncology